Evidence for Ordering of Alzheimer Disease Biomarkers
Open Access
- 1 December 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (12), 1526-1535
- https://doi.org/10.1001/archneurol.2011.183
Abstract
Biomarkers of Alzheimer disease (AD) occupy an essential place in recently formulated diagnostic criteria for AD,1-5 in which their role is to identify the pathophysiological processes underlying cognitive impairment or to help predict time to dementia.6-15 These biomarkers are also increasingly used in clinical trials as both inclusion criteria and outcome measures.Keywords
This publication has 86 references indexed in Scilit:
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Amyloid‐β associated cortical thinning in clinically normal elderlyAnnals of Neurology, 2010
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer DiseaseArchives of Neurology, 2009
- Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer TypeArchives of Neurology, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- The neuropathology of probable Alzheimer disease and mild cognitive impairmentAnnals of Neurology, 2009
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methodsJournal of Magnetic Resonance Imaging, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004